ID   A375-M
AC   CVCL_B222
SY   A375M; A375m
DR   cancercelllines; CVCL_B222
DR   Wikidata; Q54606798
RX   PubMed=1671030;
RX   PubMed=2731157;
RX   PubMed=6744277;
RX   PubMed=7648437;
RX   PubMed=7780963;
RX   PubMed=22323893;
RX   PubMed=25950383;
CC   Population: Caucasian.
CC   Characteristics: Metastatic variant of A-375. Established from a tumor obtained in nude mice injected with the parent cell line.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Omics: Exosome proteome analysis.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=1671030; DOI=10.1002/ijc.2910470211;
RA   Welch D.R., Bisi J.E., Miller B.E., Conaway D.H., Seftor E.A.,
RA   Yohem K.H., Gilmore L.B., Seftor R.E.B., Nakajima M., Hendrix M.J.C.;
RT   "Characterization of a highly invasive and spontaneously metastatic
RT   human malignant melanoma cell line.";
RL   Int. J. Cancer 47:227-237(1991).
//
RX   PubMed=2731157; DOI=10.1016/0304-3835(89)90148-1;
RA   Yohem K.H., Seftor E.A., Meyskens F.L. Jr., Hendrix M.J.C.;
RT   "Cloning efficiency of human melanoma cells is modulated after
RT   invasion through a reconstituted basement membrane.";
RL   Cancer Lett. 45:135-143(1989).
//
RX   PubMed=6744277;
RA   Kozlowski J.M., Fidler I.J., Campbell D., Xu Z.-L., Kaighn M.E.,
RA   Hart I.R.;
RT   "Metastatic behavior of human tumor cell lines grown in the nude
RT   mouse.";
RL   Cancer Res. 44:3522-3529(1984).
//
RX   PubMed=7648437; DOI=10.1089/jir.1995.15.81;
RA   Singh R.K., Gutman M., Radinsky R.;
RT   "Heterogeneity of cytokine and growth factor gene expression in human
RT   melanoma cells with different metastatic potentials.";
RL   J. Interferon Cytokine Res. 15:81-87(1995).
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=22323893; DOI=10.3109/10623329609024685;
RA   Sriramarao P., Bourdon M.A.;
RT   "Melanoma cell invasive and metastatic potential correlates with
RT   endothelial cell reorganization and tenascin expression.";
RL   Endothelium 4:85-97(1996).
//
RX   PubMed=25950383; DOI=10.1111/pcmr.12380;
RA   Lazar I., Clement E., Ducoux-Petit M., Denat L., Soldan V.,
RA   Dauvillier S., Balor S., Burlet-Schiltz O., Larue L., Muller C.,
RA   Nieto L.;
RT   "Proteome characterization of melanoma exosomes reveals a specific
RT   signature for metastatic cell lines.";
RL   Pigment Cell Melanoma Res. 28:464-475(2015).
//